TRTamara S. Reynolds

Tamara S. Reynolds

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tamara S. Reynolds has a total of 112 co-authors. Here are the top co-authors by number of shared publications:

  • Adam L. Hartman

    Division of Clinical Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Rockville, MD, USA

    1 shared publication
  • Alica Goldman

    Department of Neurology, Baylor College of Medicine, Houston, TX, USA

    1 shared publication
  • Alice D. Lam

    Department of Neurology, Massachusetts General Hospital, Harvard Medical School , Boston, MA 02114

    1 shared publication
  • Allyson L. Alexander

    Division of Pediatric Neurosurgery, Department of Neurosurgery, School of Medicine, University of Colorado Anschutz Medical Campus, Children’s Hospital Colorado, Aurora, CO, USA

    1 shared publication
  • Andrea Bernasconi

    Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada

    1 shared publication
  • Ann Hyslop

    Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, CA, USA

    1 shared publication

Latest Publications

  • Open Access

    Co-existence of TBCK encephalopathy and medium/short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (M/SCHAD) in a Puerto Rican girl

    by Shubhangi Chitnis, Tamara Reynolds, Jorge Vidaurre

    We report the case of a Puerto Rican girl who presented with multiple seizure types, epileptic spasms and severe global developmental delay. Her examination was significant for myopathic face, profound hypotonia, and areflexia. Her genetic workup revealed a homozygous pathogenic c.376C>T (p.R126X) mutation in the TBCK gene. A second homozygous likely pathogenic c.908G>T (p.G303V) mutation in the HADH gene, responsible for medium/short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (M/SCHAD), was also found. Her seizures responded dramatically to IV methylprednisolone infusions, and she has remained stable without metabolic crisis.

  • Open Access

    Highlights From the Annual Meeting of the American Epilepsy Society 2022

    by Ignacio Valencia, Allyson L. Alexander, Danielle M. Andrade, Miguel Arevalo-Astrada, Clio Rubiños, Nancy Auer, Jacquelyn L. Bainbridge, Sallie A. Baxendale, Fabrice Bartolomei, Danielle A. Becker, et al.

    With more than 6000 attendees between in-person and virtual offerings, the American Epilepsy Society Meeting 2022 in Nashville, felt as busy as in prepandemic times. An ever-growing number of physicians, scientists, and allied health professionals gathered to learn a variety of topics about epilepsy. The program was carefully tailored to meet the needs of professionals with different interests and career stages. This article summarizes the different symposia presented at the meeting. Basic science lectures addressed the primary elements of seizure generation and pathophysiology of epilepsy in different disease states. Scientists congregated to learn about anti-seizure medications, mechanisms of action, and new tools to treat epilepsy including surgery and neurostimulation. Some symposia were also dedicated to discuss epilepsy comorbidities and practical issues regarding epilepsy care. An increasing number of patient advocates discussing their stories were intertwined within scientific activities. Many smaller group sessions targeted more specific topics to encourage member participation, including Special Interest Groups, Investigator, and Skills Workshops. Special lectures included the renown Hoyer and Lombroso, an ILAE/IBE joint session, a spotlight on the impact of Dobbs v. Jackson on reproductive health in epilepsy, and a joint session with the NAEC on coding and reimbursement policies. The hot topics symposium was focused on traumatic brain injury and post-traumatic epilepsy. A balanced collaboration with the industry allowed presentations of the latest pharmaceutical and engineering advances in satellite symposia.